After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi

Cyclacel Pharmaceuticals once had high hopes for sapacitabine. But, despite making it all the way to phase 3 in acute myeloid leukemia (AML) as well as midstage studies for other cancers, the biotech has decided to give up and hand the rights back to Daiichi Sankyo.